<DOC>
	<DOCNO>NCT01111019</DOCNO>
	<brief_summary>This study conduct describe efficacy safety recombinant human growth hormone ( r-hGH ) treatment Saizen® child hypochondroplasia .</brief_summary>
	<brief_title>Efficacy Safety Evaluation Recombinant Human Growth Hormone ( r-hGH ) , Saizen® , Population Children With Hypochondroplasia , Treated Least 3 Years Until Near Final Height , When Applicable , Comparison With Historic Cohort Non-treated Children</brief_title>
	<detailed_description />
	<mesh_term>Dwarfism</mesh_term>
	<mesh_term>Lordosis</mesh_term>
	<mesh_term>Limb Deformities , Congenital</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Male female child hypochondroplasia define disproportional short limb height Xray evidence shorten long bone failure increase interpedicular distance lumbar vertebra L1 L5 Result genetic analysis mutation gene FGFR3 already know ongoing analysis begin study Chronological age great equal 3 year Height chronological age less equal 2 SDS Bone age less equal 11 year girls 13 year boys A write informed consent begin pretreatment period must obtain parent ( ) /legal guardian ( ) . Children able understand trial personally sign date write informed consent Additional inclusion criterion study prolongation : Bone age Month 36 Month 60 compatible treatment prolongation accord investigator opinion Subject still rhGH treatment Saizen® Month 36 Month 60 Height gain great equal + 1 SDS 2 first year treatment treatment prolongation Month 36 growth velocity great equal 5 centimeter ( cm ) per year , bone age le 14 year females less 16 year male treatment prolongation Month 60 According investigator opinion , gene mutation subject connection observe side effect 3 5 first year treatment An update write informed consent must obtain parent ( ) /legal guardian ( ) start study prolongation . Children able understand trial personally sign date write informed consent Turner 's Syndrome girl Active malignant neoplastic disease Severe congenital malformation Proliferative preproliferative diabetic retinopathy Evidence progression recurrence underlie intracranial space occupy lesion Severe psychomotor retardation Diabetes mellitus history significant glucose intolerance define fast blood glucose great 6.4 millimole per liter ( mmol/L ) Known renal insufficiency define serum creatinine level 1.0 milligram per deciliter ( mg/dL ) ( 88 micromole per liter [ mcmol/L ] ) Known hepatic disease define elevate liver enzymes total bilirubin ( * 2 Normal ) Current congestive heart failure , untreated hypertension , serious chronic edema cause Chronic infectious disease History intracranial hypertension papilledema Previous ongoing treatment sex steroid therapy estrogens testosterone Previous ongoing treatment therapy may directly influence growth , include Growth Hormone ( GH ) , Growth Hormone Releasing Hormone ( GHRH ) long duration corticosteroid therapy Known hypersensitivity somatropin excipients Epiphyseal fusion Participation clinical study within 30 day precede study entry Pregnant female</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Hypochondroplasia</keyword>
	<keyword>Skeletal dysplasia</keyword>
	<keyword>Growth</keyword>
	<keyword>Growth Hormone</keyword>
	<keyword>Recombinant-human Growth Hormone</keyword>
</DOC>